Login to Your Account

Biosceptre reports POC phase I cancer data, plans funding round

By Nuala Moran
Staff Writer

Tuesday, July 22, 2014
LONDON – Biosceptre Ltd. announced positive results from a U.S. phase I study of its lead antibody, BIL-010t, providing proof of concept for what the company said is a highly specific target found in at least 20 different cancers, and paving the way for a £20 million (US$34.2 million) funding round to take two products through to phase IIb development.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription